A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple ascending doses of VX-708 in healthy participants

Detailed Description
-----------------
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Official Title
-----------------
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-708 in Healthy Subjects

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: VX-708
* Drug: Itraconazole
* Drug: Midazolam
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Male and female of non-childbearing potential are eligible Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m^2) A total body weight greater than (>) 50 kg Key Exclusion Criteria: History of febrile illness or other acute illness within 14 days before the first dose of study drug History of cardiac dysrhythmias Part A Cohorts with Midazolam DDI Evaluation (Cohort A4) Only Hypersensitivity to midazolam or benzodiazepines Part A Cohorts with CSF Sampling (Cohorts A2 and A3) Only Hypersensitivity to local anesthetic for lumbar puncture History of conditions leading to increased intracranial pressure (e.g., brain tumor, idiopathic intracranial hypertension, venous sinus thrombosis) Part B Only Hypersensitivity to itraconazole Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Part A: VX-708 (Cohort A1-A3)<br>Participants will receive multiple doses of one of different dose levels of VX-708 under fasting condition. | Drug: VX-708<br>* Solution for intravenous (IV) administration.<br>|
| Placebo Comparator: Part A: Placebo<br>Participants will receive placebo matched to VX-708. | Drug: Placebo<br>* Placebo matched to VX-708 for IV administration.<br>|
| Experimental: Part A: Midazolam With or Without VX-708 (Cohort A4)<br>Participants will receive a single dose of Midazolam with or without VX-708 under fasting condition. | Drug: VX-708<br>* Solution for intravenous (IV) administration.<br>Drug: Midazolam<br>* Solution for oral administration.<br>|
| Experimental: Part B: VX-708 With Itraconazole<br>Participants will receive a single dose of VX-708 in treatment period 1, followed by itraconazole, which will be dosed daily with a single dose of VX-708 administered in treatment period 2 under fasting conditions. A washout period of 6 days will be maintained between the 2 treatment periods. | Drug: VX-708<br>* Solution for intravenous (IV) administration.<br>Drug: Itraconazole<br>* Solution for oral administration.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) |  | Day 1 up to Day 30 | 
| Part A: Safety and Tolerability as Assessed by Number of Participants With Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses |  | Day 1 up to Day 30 | 
| Part A: Continuous Pulse Oximetry Monitoring as assessed by oxygen saturation for Cohort A4 |  | Pre-dose up to 6 hours Post-dose | 
| Part A: Infusion Nurses Society (INS) Visual Infusion Phlebitis (VIP) Score Monitoring |  | Day 1 up to Day 30 | 
| Part B: Area Under the Plasma Concentration Versus Time Curve from the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-708 in the Absence or Presence of Itraconazole |  | Day 1 up to Day 16 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part A: Area Under the Plasma Concentration Versus Time Curve from the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-708 |  | Day 1 up to Day 14 | 
| Part A: Area Under the Concentration Versus Time Curve from the Time of Dosing Extrapolated to Infinity (AUC0-inf) of Midazolam and 1-hydroxy-midazolam in the Absence or Presence of VX-708 (Cohort A4) |  | Day 1 up to Day 14 | 
| Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) |  | Day 1 up to Day 32 | 
| Part B: Infusion Nurses Society (INS) Visual Infusion Phlebitis (VIP) Score |  | Day 1 up to Day 30 |